双抗和ADC药物为晚期肿瘤患者带来曙光

Core Insights - Traditional chemotherapy has been the main weapon against cancer, but advancements in targeted therapies and immunotherapies have provided new hope for patients. However, many still face challenges such as drug resistance and treatment bottlenecks. The emergence of bispecific antibodies and antibody-drug conjugates (ADCs) offers renewed optimism for late-stage cancer patients [1][2][3] Group 1: Patient Experiences - A 62-year-old patient diagnosed with late-stage lung cancer experienced significant relief from symptoms after using targeted therapy, but faced disease progression and treatment failure with subsequent therapies. After switching to a bispecific antibody, the patient saw a reduction in pleural effusion and improvement in overall health after just two doses [1] - A 46-year-old patient with late-stage gastric cancer underwent multiple lines of treatment without success until an ADC was introduced. This therapy not only halted gastrointestinal bleeding but also significantly reduced the size of liver metastases after three cycles of treatment, demonstrating the effectiveness of targeted drug delivery [2] Group 2: Treatment Mechanisms - Bispecific antibodies work by activating the immune system while simultaneously inhibiting tumor blood supply, thus broadening the treatment targets and enhancing efficacy against various cancer types [1] - ADCs combine targeted therapy with chemotherapy, allowing for precise delivery of cytotoxic agents directly to cancer cells, resulting in minimal damage to normal cells and improved treatment outcomes [2][3] Group 3: Clinical Considerations - While bispecific antibodies and ADCs represent significant advancements in cancer treatment, they are not suitable for all late-stage cancer patients. A thorough assessment of the patient's health status, tumor type, stage, and genetic factors is essential for developing an appropriate treatment plan [3]